In the study researchers at Dana Farber Cancer Institute and the MAYO Clinic is based on data from a large observational study nested within a clinical trial. The results align with earlier studies that also showed a link between coffee consumption and improved outcomes in patients with localized colorectal cancer. The findings appear in the Sept. 17, 2020 JAMA Oncology.
The researchers analyzed data from 1,171 patients who had been participating in a large clinical trial comparing different combination chemotherapies for metastatic colorectal cancer.
That trial collected information through questionnaires over a period of years. When diagnosed and treated for metastatic colorectal cancer, the researchers took another look at the data from those patients collected from the clinical trial.
They found that those who reported drinking two to three cups of coffee a day were likely to live longer overall than those who didn’t drink coffee. Patients who drank four or more cups of coffee a day had an even greater benefit in survival.
“It’s known that several compounds in coffee have antioxidant, anti-inflammatory, and other properties that may be active against cancer,” said co-first author of the study Dana-Farber’s Chen Yuan, ScD in a press release.
The researchers caution that the findings enabled investigators to establish an association, but not a cause-and-effect relationship, between coffee drinking and reduced risk of cancer progression and death among study participants.
As a result, the study doesn’t provide sufficient grounds for recommending, at this point, that people with advanced or metastatic colorectal cancer start drinking coffee on a daily basis or increase their consumption of the drink, researchers say.
No comments:
Post a Comment